Navigation Links
Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Date:3/26/2009

Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials, including possible delays in initiating or completing the trials and safety and efficacy results; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
2. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
3. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
4. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
5. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
6. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
7. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
8. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
9. Novavax CEO to Present at Piper Jaffray 20th Annual Healthcare Conference
10. Novavax CEO to Present at Lazard Capital Markets 5th Annual Healthcare Conference
11. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 2014 Deep ... is a professional and in-depth research report ... provides basic Seaweed Fertilizer information, including Seaweed ... structure as well as industry overview. This ... domestic market as well as global industry ...
(Date:8/21/2014)... 21, 2014  Decision Resources Group finds that ... and Mexico currently ... newly approved agents, the anticipated label extension of ... launch of emerging biologics will substantially increase the ... emerging IL-5 inhibitors will introduce a new dynamic to ...
(Date:8/21/2014)... NJ (PRWEB) August 21, 2014 ... personal selling optimization technology and services for Life ... of “Grading Pharma’s Use of New Commercial Sales ... Measurement & Analytics. , The article examines some ... yield that are being tested in the pharmaceutical ...
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
Breaking Biology Technology:Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2
... EMERYVILLE, Calif., Jan. 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... present,at the JPMorgan Healthcare Conference on Monday, January ... access a live webcast of the,presentation at:, ... listeners log on 15 minutes early in order ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... has filed a protocol with the U.S. ... 1/2 clinical trial for patients with,metastatic ovarian, ... and intraperitoneal administration of REOLYSIN(R), Oncolytics,proprietary formulation ...
... LOS GATOS, Calif., Dec. 31 Three ... announced that it has received 510(k) clearance,from ... for its WorkstationOne(TM),Breast Imaging Workstation. WorkstationOne is ... mammography images, and was developed with,the goal ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R) 2
(Date:8/20/2014)... scientists have discovered that acral melanomas the rare type ... are genetically distinct from other more common types of ... in the journal Pigment Cell & Melanoma Research . ... hands, soles of the feet, nail-beds and other hairless parts ... it,s not caused by UV damage from the sun. , ...
(Date:8/20/2014)... sunscreen and seawater signals a relaxing trip to the ... beach vacation comes with an environmental hitch. When certain ... they can become toxic to some of the ocean,s ... other marine animals. Their study appears in the ACS ... Tovar-Sanchez and David Snchez-Quiles point out that other than ...
(Date:8/20/2014)... Wu Feng has built upon a National Science Foundation ... Cloud" program, and synergistically complemented it with subsequent collaborative ... Force on "big computing" for mini-drones and a $1 ... Health on "big data" for the life sciences. , ... each grant, he was able to tell a much ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... are under attack. Since 2006, more than a million have ... there has not been enough evidence to implicate the suspectuntil ... Geomyces destructans is the causal agent of White-nose Syndrome (WNS), ... is coauthored by Justin Boyles, a post-doctoral research associate in ...
... Dalhousie University in Nova Scotia have identified a key ... growth if their findings are confirmed. In ... journal of the American Association for Cancer Research, lead ... Biochemistry and Molecular Biology and Pathology, and Canada Research ...
... alphabet expanded. Scientists discovered that an extra letter or ... cells and brain cells. Now, researchers at Emory ... by that letter in the brains of mice, observing ... during development and aging. Those patterns, stable or ...
Cached Biology News:UT scientist helps confirm link between fungus and bat epidemic 2Key driver of metastasis identified 2Patterns of new DNA letter in brain suggest distinct function 2
Recombinant Feline IFN-alpha...
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... MaV203 Competent Yeast Cells are designed ... (Figure 1). S. cerevisiae strain MaV203 contains ... genes for use with GAL4-based two-hybrid systems. ... mutations for selection of ProQuest bait and ...
Biology Products: